**Table 1: Baseline characteristics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **All Patients**  **Median (IQR)**  **n=337** | **NT**  **Median (IQR)**  **n=203** | **AP**  **Median (IQR)**  **n=83** | **AC**  **Median (IQR)**  **n=51** | **p value** |
| ***Preoperative*** |  |  |  |  |  |
| **Age (years old)** | **67 (54-85)** | **65 (54-82)** | **67 (58-75)** | **70 (55-85)** | **0.015** |
| **Preoperative PSA (ng/dL)** | **5.8 (0.7-25)** | **5.7 (0.7-16.7)** | **6.5 (1-25)** | **5.8 (2.6-12.2)** | **0.182** |
| **Prostate volume (mL)** | **130 (100-340)** | **132 (100-340)** | **138 (101-189)** | **129 (103-265)** | **0.371** |
| **ASA score (%)** |  |  |  |  | **<0.001** |
| **I** | **31 (9.2)** | **25 (12.3)** | **6 (7.2)** | **0 (0)** |  |
| **II** | **192 (57)** | **158 (77.8)** | **25 (30.1)** | **9 (17.6)** |  |
| **III** | **110 (32.6)** | **19 (9.4)** | **50 (60.2)** | **41 (80.4)** |  |
| **IV** | **4 (1.2)** | **1 (0.5)** | **2 (2.4)** | **1 (2)** |  |
| **Previous prostate biopsy** | **58 (17.2)** | **36 (17.7)** | **12 (14.5)** | **10 (19.6)** | **0.705** |
| **Q max** | **7.8 (3.4-19)** | **8 (3.4-19)** | **7 (4-16)** | **6.5 (6-18)** | **0.545** |
| **IPSS** | **25 (13-32)** | **25 (16-32)** | **26 (13-30)** | **24 (19-30)** | **0.155** |
| **PVR** | **100 (60-140)** | **110 (70-120)** | **100 (75-140)** | **90 (60-130)** | **0.450** |
| **QoL** | **5 (3-6)** | **4 (3-6)** | **5 (3-6)** | **5 (4-6)** | **0.244** |

*IQR: Inter Quantile Range, NT: Non-Treatment, AP: Antiplatelet therapy, AC:Anticoagulation therapy, PSA:Prostate specific antigen, ASA:American Society of Anesthesiologists, Q max: Maximum flow rate, IPSS: International prostate symptoms score, PVR: Postvoiding residual volume, and QoL: Quality of life.*